Abstract PS5-12-16: A Phase 2 Trial of (Z)-endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+, HER2-, Breast Cancer (EVANGELINE)
M. P. Goetz(Mayo Clinic in Arizona), S. C. Quay(Atossa Therapeutics (United States)), Felipe Batalini(Beth Israel Deaconess Medical Center), Vrushali Dabak(Henry Ford Hospital), Lida A. Mina(Mayo Clinic in Arizona), Mara A. Piltin(Mayo Clinic), H. Erickson(Atossa Therapeutics (United States)), Amy C. Degnim(Cancer Clinic), J. M. Reid(Mayo Clinic), L. Beaulieu(Atossa Therapeutics (United States)), N. A. Bagegni(University of Minnesota Rochester), J. R. Hawse(Mayo Clinic), D. Flora(St. Elizabeth Healthcare), R. A. Leon-Ferre(Mayo Clinic in Arizona), C. Lopez(Atossa Therapeutics (United States)), K. N. Hunt(Mayo Clinic in Arizona), B. A. Sarah(Mayo Clinic), E. Sima(University of Arizona), J. Jakub(Jacksonville College), K. V. Giridhar(Mayo Clinic in Arizona), J. N. Ingle(Mayo Clinic), W. J. Irvin(Virginia Cancer Institute), V. J. Suman(Mayo Clinic in Florida), K. Seema(Northwestern University), S. S. Hammer(Atossa Therapeutics (United States)), J. C. Boughey(Mayo Clinic), J. M. Jones(Avera Health), Matthew J. Schellenberg(Mayo Clinic), V. Abramson(Vanderbilt University), Pooja Advani(Jacksonville College)
Cited by 0
Related Papers
Deficiency of terminal ADP‐ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease
|The EMBO Journal|2013|309
Recognition and maturation of effector RNAs in a CRISPR interference pathway
|Nature Structural & Molecular Biology|2011|166
Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2·DNA and Top2·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)
|Journal of Biological Chemistry|2014|120